Surgical pathologie staging in apparent stage I endometrial carcinoma

Costantino Mangioni(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ettore Marubini(University of Milan), G. De Palo(Fondazione IRCCS Istituto Nazionale dei Tumori)
International Journal of Gynecological Cancer
October 1, 1993
10.1046/j.1525-1438.1993.03060373.x
Cited by 19

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Dietary Factors and Risk of Breast Cancer: Combined Analysis of 12 Case--Control Studies
|JNCI Journal of the National Cancer Institute|1990|756
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530